Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Wu 6-marker phage peptide panel for Lung Cancer

Wu 6-marker phage peptide panel for Lung Cancer

Basics

Attributes

QA State: Curated
Short Name:
HGNC Name:

The six-phage peptide detector stands out as a promising diagnostic biomarker for NSCLC. The peptide panel could be used to diagnose non-small cell lung cancer and to differentiate between non-small cell lung cancer and chronic obstructive pulmonary diseases. One of the six phage peptides shows 100% homology to olfactomedin 1. (Clin Cancer Res. 2010 Jul 15;16(14):3760-8. doi: 10.1158/1078-0432.CCR-10-0193) The other five peptides were homologous to proteins in a blastp search, but the homology was not high enough to positively identify the peptides.

Panel Details

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

The six-phage peptide detector could be used to diagnose NSCLC at early stage and discriminate NSCLC and chronic obstructive pulmonary diseases. Chemotherapy significantly reduced the seroreactivity of the six-phage peptide clones. The six-phage peptide detector can be used as a novel method for noninvasive diagnosis and screening of NSCLC in high-risk populations. However, it is unlikely to be used as biomarkers for indicating the relapse of NSCLC after chemotherapy. (Clin Cancer Res. 2010 Jul 15;16(14):3760-8. doi: 10.1158/1078-0432.CCR-10-0193)

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Organs

No associated resources found.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.